We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Screening for Genetic Mutations Predict Preterm Birth Defects

By Biotechdaily staff writers
Posted on 12 Feb 2008
Genetic mutations in the enzyme methylenetetrahydrofolate reductase (MTHFR) and coagulation protein factor V appear to have significant association with blood clots and tissue injury to the placenta and developing baby.

MTHFR is an enzyme related to amino acid metabolism. More...
Intrauterine growth restriction results in malnutrition of the developing fetus and babies of low birth weight, and can be related to a host of factors usually reflective of the mother's health, including infection, high blood pressure, and use of tobacco, alcohol, or illicit drugs. Factor V is a protein of the coagulation system, sometimes referred to as proaccelerin or labile factor.

Defined as any birth prior to 37 weeks gestation, preterm birth affects some 12% of pregnancies in the United States. A recent study from the U.S. Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) found that preterm birth contributed to more than a third of infant deaths--twice as many as previously thought and making it the leading cause of infant deaths --yet the underlying causes of premature birth remain poorly understood. Babies who do survive face risks related to cerebral palsy, mental retardation, chronic lung disease, and vision and hearing loss, as well as other developmental problems.

Scientists from the University of Pittsburgh School of Medicine (Pittsburgh, PA, USA) analyzed DNA from placental tissue samples and cord blood from 111 women and their babies, finding that one fetal single nucleotide polymorphism (SNP) in MTHFR and one fetal SNP in factor V demonstrated "highly significant association with thrombotic and inflammatory lesions,” irrespective of adjustment for maternal race, smoking, and lower genital tract infection, all of which can contribute to genetic mutation. Women and babies with MTHFR mutation were 4.2 times more likely to exhibit blood clots and injury to placental tissue than those without the mutation. For those with factor V mutation, the association was less pronounced, but still elevated.

"This indicates a possible genetic predisposition to a condition of real clinical consequence in terms of intrauterine growth restriction, preeclampsia, and spontaneous preterm birth,” said Hyagriv Simhan, M.D., assistant professor of obstetrics, gynecology, and reproductive sciences at the University of Pittsburgh School of Medicine.

The study was presented at the 28th annual meeting of the Society for Maternal-Fetal Medicine, which was held in Dallas (TX, USA) from January 28 to February 2, 2008.


Related Links:
U.S. Centers for Disease Control and Prevention
University of Pittsburgh School of Medicine

New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Specimen Radiography System
TrueView 200 Pro
New
Candida Glabrata Test
ELIchrom Glabrata
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.